Table S4.
Resource use and costs associated with PsO, PsA, and AS treatment
| Component | PsO
|
PsA
|
AS
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| % | Frequency per year | Unit cost | % | Frequency per year | Unit cost | % | Frequency per year | Unit cost | |
| Physician visit | 10 | 5.0 | €66.00 | 100 | 10.7 | €66.00 | 100 | 10.8 | €66.00 |
| Emergency room visit | – | – | – | 20 | 1.8 | €241.05 | 22 | 2 | €241.05 |
| Phototherapy (narrow band UVB) | 16 | 24.0 | €54.00 | – | – | – | – | – | – |
| NSAIDsa | 45 | – | €1,446.31 | 52 | – | €1,446.31 | 22 | – | €1,446.31 |
| DMARDsa | 45 | – | €223.90 | 52 | – | €223.90 | 22 | – | €223.90 |
Notes: Cost data obtained from Italian national formulary;1 phototherapy-related data from De Compadri and Koleva;2 frequency data for PsO from NICE clinical guidance3 and for PsA and AS from Greenberg et al.4
a
For NSAIDs and DMARDs, cost has been estimated as weighted cost as the global model.
Abbreviations: AS, ankylosing spondylitis; DMARD, disease-modifying antirheumatic drugl NSAID, nonsteroidal anti-inflammatory drug; PsA, psoriatic arthritis; PsO, psoriasis.